Accelerate Transepithelial Corneal Collagen Crosslinking for Progressive Keratoconus
Narrative Responses:
Purpose
To evaluate the safety, efficacy, and stability of accelerate transepithelial corneal collagen crosslinking in progressive keratoconus.
Methods
This prospective study included 27 eyes of 27 patients with progressive keratoconus diagnosis whom underwent corneal collagen crosslinking between January 2013 and September 2013. The solution used was TE-riboflavin (Peschke Ltd, Germany) and the Ultraviolet-A treatment was performed with CCL-VARIO (Peschke Ltd, Germany) with 5 minutes of irradiation (18mW) and 30 minutes of impregnation. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), manifest refraction, demarcation line using anterior segment OCT (optical coherence tomography), and Scheimpflug imaging parameters where evaluated at pre and postoperatively day one, and 1, 3, 6 and 9 months.
Results
Mean crosslinking deep was 179.16 um at 1.5 mm from the center of the cornea compared with 255.45 um at the center of the cornea. Mean diameter of the crosslinking was 3.63 mm visualized by AS-OCT. There was a not statistically significant difference between pre and postoperative pachymetry at the center and the thinnest point of the cornea (p > 0.05 in all visits). Mean maximum posterior elevation values decrease from 36.02 um to 33.11 um (p = 0.09). Mean maximum keratometry at preoperative and postoperative follow up (6 month) was 50.11 and 50.75 diopters (D) respectively (p = 0.45).
Conclusion
Accelerate transepithelial crosslinking is safe and efficacy to stop the progression of the keratoconus. AS-OCT images showed that the intended depth of crosslinking is achieved within the central area of the cornea.